Q-omics provides the consensus-scored RN7SL351P profile across patient tissues and cancer cell-line models. RN7SL351P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RN7SL351P is differentially expressed in 8, with the highest sampling consensus in PAAD. Additionally, RN7SL351P RNA expression shows 11,523 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KICH, PAAD, and ESCA as cancer lineages where RN7SL351P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL351P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL351P survival associations across molecular data types. RN7SL351P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL351P RNA expression–survival associations across cancer types. High RN7SL351P expression shows unfavorable associations in KICH, CHOL, ACC and KIRC, but favorable associations in UCS and BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RN7SL351P RNA expression.
This table summarizes RN7SL351P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL351P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL351P shows lower tumor expression in PAAD, KIRP, THCA and UCEC and higher tumor expression in STAD and BRCA. The PAAD box plot shows higher RN7SL351P RNA expression in normal versus tumor tissue (log2 FC = −0.650, t-test p = .037).
This table shows molecular features associated with RN7SL351P in patient tissues and cancer cell lines. In patient samples, RN7SL351P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
